Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
IGY Life Sciences has optimized the sustainable generation of highly specific and efficacious egg-derived IgY antibodies for human and animal health. The company’s pipeline includes marketed immune and sports health products, and lead compounds against COVID-19 and African swine fever.
Carisma Therapeutics is developing unique CAR macrophage therapies to treat solid tumors. The company’s lead CAR-M program, CT-0508, is ready to enter phase 1 testing.
Combining the precision of antibody targeting with α-amanitin, a novel payload, Heidelberg Pharma has developed a powerful therapeutic platform, with the potential to treat a broad range of cancers.
3T Biosciences has developed an immune response-guided approach for identifying pharmacologically active T cell receptors and their targets in solid tumors. With a pipeline of therapeutics targeting novel tumor antigens, 3T is seeking partners to advance these programs.
ExosomeDx harnesses biological information from exosomes for biomarker discovery and diagnostic development. The company’s pipeline of products includes the ExoDx Prostate test, the first exosome-based liquid biopsy on the market, and various discovery platforms to help solve biopharma’s biomarker-related needs.
Precision NanoSystems is developing nanoparticle-delivered drugs through its NanoAssemblr technology, helping companies solve drug delivery challenges in cancer, rare diseases and infectious diseases.
Rakuten Medical, a clinical-stage privately funded biotechnology company, is developing first-in-class targeted cancer therapies based on Illuminox, a new platform with the potential to treat many types of solid tumor, one of the leading causes of death globally.
Employing its deep understanding of G-protein coupled receptors (GPCRs) the Beacon Discovery team has delivered more than 20 compounds into clinical development over the past two decades, and is now working with partners to unlock the therapeutic value of challenging receptors in this class.
With expertise, capabilities, and capacity in abundance, the Cellex Group is an experienced facility worldwide for allogeneic bone marrow, peripheral blood stem cell and other cellular blood components, and is now growing to become a complete service provider for cellular immunotherapy products.
GEMoaB’s three proprietary technology platforms have produced a deep pipeline of immunotherapy assets, three of which are currently being investigated in clinical studies, providing the basis for future growth.
IGY Life Sciences has optimized the sustainable generation of highly specific and efficacious egg-derived IgY antibodies for human and animal health. The company’s pipeline includes marketed immune and sports health products, and lead compounds against COVID-19 and African swine fever.
Life-threatening respiratory diseases remain a key therapeutic area of focus for multinational company Zambon. The company has two phase 3 development programs underway for the treatment of bronchiolitis obliterans syndrome (BOS) and non-cystic fibrosis bronchiectasis (NCFB).
ENPICOM’s ImmunoGenomiX (IGX) Platform offers state-of-the-art immunomics data analysis, management and visualization for academic researchers, drug developers, and related service providers.
DTx Pharma’s next-generation, fatty acid ligand-conjugated oligonucleotides enable efficient delivery of RNA-based therapeutics to cells and tissues throughout the body. With three disease franchises—ocular, neuromuscular and central nervous system (CNS), DTx is seeking partners to realize the potential of its platform.
Karma Oncology combines an agile and adaptable business model with expertise in oncology clinical trials to provide bespoke contract clinical research services for biotechnology companies globally.
Privately held Creatv MicroTech has developed LifeTracDx tests to detect cancer at the earliest stages, and for providing diagnoses to guide cancer treatments, thereby saving and improving lives.
Using its SmartCube platform along with machine learning algorithms, PsychoGenics has a powerful tool for the discovery of novel neuropsychiatric compounds.
RubrYc Therapeutics has established an antibody discovery engine for the development of epitope-targeted biotherapeutics. Through machine learning, the platform helps reveal natural subdominant and alternative epitopes to target for optimized bio-superior design and as access points to traditionally ‘undruggable’ proteins.
